On September 11, Novartis announced,Its heavy-duty anti-tumor drug Toripalimab®(Capmatinib Hydrochloride Tablets)Successfully approved for new indications in China, for the treatment ofCarrying Mesenchymal Epithelial Transition Factor(MET) Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 14 Skipping Mutation(NSCLC) Adult patients. Screenshot source: Novartis official WeChatCapmatinib is an orally available, highly selective, and specific MET receptor tyrosine kinase inhibitor that effectively inhibits the phosphorylation of MET and MET-mediated downstream signaling proteins, thereby suppressing tumor cell proliferation and migration, and efficiently inducing apoptosis, demonstrating anti-tumor activity.As one of Novartis' key products in the field of lung cancer, capmatinib tablets were approved for use in China in 2024.Adult patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations who have not received systemic treatment。The approval of this new indication further expands the applicable population for capmatinib tablets. More NSCLC patients with METex14 skipping mutations are expected to achieve both prolonged survival and improved quality of life through this precise treatment option.
